On February 27, 2021, the FDA issued an Emergency Use Authorization for the Janssen COVID-19 Vaccine in the United States. The District of Columbia Department of Health (DC Health) continues to implement distribution administration recommendations as outlined in the District’s COVID-19 Vaccination Plan. The Janssen vaccine has been shown to be safe and effective as determined by the interim analysis of the international clinical trial COV3001 which involves more than 40,000 individuals worldwide drawn from diverse ethnic and socioeconomic backgrounds including those with underlying medical conditions.  Current evidence demonstrates that the known and potential benefits of the vaccine outweigh the known and potential harms associated with COVID-19. This health notice provides information on safe administration, clinical considerations, reporting requirements, and highlights important resources for healthcare providers.